Dr. Reddy's Laboratories Revenue, Profits - RDY Quarterly Income Statement

Add to My Stocks
$35.06 $2.04 (6.18%) RDY stock closing price Jun 15, 2018 (Closing)

Fundamental analysis of RDY stock involves analyzing its financial statements, apart from checking the Dr. Reddy's Laboratories stock price. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. Like any other income statement, the RDY income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a QoQ revenue decline of -7.83% when compared to the same period in the past. One also needs to look at Dr. Reddy's Laboratories assets, operating expenses and Dr. Reddy's Laboratories free cash flow. The Dr. Reddy's Laboratories profit and loss statement shows revenue of $549.32M for 2018 Q4. Revenue has decreased by -7.83% QoQ for RDY stock.

View and download details of revenue and profits for Dr. Reddy's Laboratories for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Apr - Mar2018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q3
Dr. Reddy's Laboratories Revenues or Net Sales
Cost Of Goods Sold (COGS)-132.82M258.05M258.32M249M293.31M223.29M236.4M210M229.97M244.55M
Dr. Reddy's Laboratories Gross Profit
Research & Development Expense-72.33M65.13M79M78.83M72.96M78.21M71M68.88M62.24M
Selling General & Admin Expense685.35M181.89M170.32M179M181.33M164.22M172.45M181M159.51M181.13M
Income Before Depreciation Depletion Amortization245.46M77.63M59.4M6M54.99M85.23M50.78M17M68.27M115.18M
Depreciation Depletion Amortization166.96M---------
Non Operating Income-17.63M4.53M9M5.86M4.52M8.62M10M13.18M6.99M
Interest Expense2.61M3.13M3.47M3M5.55M2.56M1.89M2M52.76M6.96M
Dr. Reddy's Laboratories Pretax Income
Provision for Income Taxes8.56M40.31M16.02M3M1.76M17.97M13.27M7M24.88M27.17M
Investment Gains Losses5.33M---------
Other Income----------
Income Before Extraordinaries & Disc Operations46.96M52M44M9M48M69M44M18.88M11M88M
Extraordinary Items & Discontinued Operations----------
Dr. Reddy's Laboratories Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS166.23M162.5M169.23M150M165.52M164.29M162.96M169.53M157.14M172.55M
Average Shares used to compute Basic EPS165.95M162.5M169.23M150M165.52M164.29M162.96M169.53M157.14M172.55M
Income Before Nonrecurring Items46.96M66.57M44M9M48M69M44M18.88M11M88M
Income from Nonrecurring Items--14.57M--------
Dr. Reddy's Laboratories Earnings Per Share Basic Net
Dr. Reddy's Laboratories Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items0.280.410.
Preferred Dividends Acc Pd----------
Dividends Common0.000.00--------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

It is very helpful to read a report on Dr. Reddy's Laboratories stock analysis. An investor must check the following items in an income statement:

  • Revenue: The money received by selling of goods or services comes under this line item. A QoQ growth - See: Dr. Reddy's Laboratories revenue chart, implies that the company is growing. It has not been the case with Dr. Reddy's Laboratories. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. RDY stock had a poor bottom line growth.

The income statement is also called the profit and loss statement. Apart from the RDY income statement, one can check the Dr. Reddy's Laboratories historical stock prices to check how the price has moved with time.

Dr. Reddy's Laboratories Income Statement - Key Financial Ratios

PE Ratio (price earnings ratio)
PS Ratio (price sales ratio)
Operating Margin
Net Profit Margin
Dividend Yield

Other Income Statements - Dr.Reddy's Laboratories Ltd (ADR) Industry Peers

Mylan income statement, Novartis income statement, Sanofi income statement, Teva Pharmaceutical income statement